Profile data is unavailable for this security.
About the company
Smith & Nephew plc is a medical technology company. The Company is engaged in designing and manufacturing technology. It supports healthcare professionals to return their patients to health and mobility by helping them to perform. It serves its customers through global franchises, which includes Orthopaedics, Sports Medicine and Ear, Nose and Throat (ENT) and Advanced Wound Management. The Orthopaedics includes a range of Hip and Knee Implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that allow surgeons, and Trauma products used to stabilize severe fractures and correct bone deformities. Its Sports Medicine and ENT businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a set of products to meet clinical needs, to help healthcare professionals reduce the human and economic consequences of wounds.
- Revenue in GBP (TTM)3.78bn
- Net income in GBP408.00m
- Incorporated1937
- Employees18.00k
- LocationSmith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
- Phone+44 207 401 7646
- Fax+44 207 930 3353
- Websitehttp://www.smith-nephew.com/
More ▼
Mergers & acquisitions
| Acquired company | SN.:LSE since announced | Transaction value |
|---|---|---|
| Engage Surgical | 1.33% | 135.00m |
Data delayed at least 20 minutes, as of Jan 21 2022 16:38 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elekta AB (publ) | 1.12bn | 94.09m | 2.92bn | 4.52k | 32.13 | 4.63 | 15.85 | 2.61 | 3.07 | 3.07 | 36.52 | 21.31 | 0.5656 | 3.54 | 2.74 | 3,327,134.00 | 4.74 | 4.20 | 8.46 | 7.59 | 38.27 | 41.92 | 8.38 | 7.80 | 0.8643 | -- | 0.4091 | 55.68 | -5.74 | 4.17 | 15.68 | 55.71 | 1.54 | 34.49 |
| Ambu A/S | 451.16m | 27.77m | 3.36bn | 4.58k | 137.08 | 8.59 | 65.12 | 7.45 | 0.9761 | 0.9761 | 15.79 | 15.58 | 0.7525 | 2.39 | 6.58 | 875,436.30 | 4.63 | 7.12 | 5.71 | 9.04 | 62.37 | 60.09 | 6.16 | 9.39 | 0.8776 | 11.13 | 0.1724 | 30.15 | 12.50 | 14.00 | 2.49 | -0.2412 | 32.50 | -1.32 |
| ConvaTec Group PLC | 1.47bn | 102.70m | 3.51bn | 9.69k | 34.48 | 2.78 | 13.77 | 2.39 | 0.0505 | 0.0505 | 0.7283 | 0.627 | 0.5448 | 3.14 | 6.31 | 151,860.30 | 3.80 | 1.47 | 4.30 | 1.63 | 54.28 | 53.67 | 6.98 | 3.00 | 1.83 | 5.21 | 0.4724 | 165.15 | 3.67 | 2.79 | 1,047.96 | -- | 18.05 | -- |
| Oxford Nanopore Technologies PLC | 124.50m | -70.61m | 4.45bn | 690.00 | -- | 12.29 | -- | 35.76 | -0.0868 | -0.0868 | 0.1531 | 0.4403 | -- | -- | -- | 205,452.10 | -- | -- | -- | -- | 48.99 | -- | -56.72 | -- | 5.82 | -250.39 | 0.0624 | -- | 118.71 | -- | 15.19 | -- | -- | -- |
| GN Store Nord A/S | 1.77bn | 209.22m | 6.16bn | 7.10k | 27.84 | 8.79 | 18.24 | 3.48 | 14.24 | 14.24 | 120.56 | 45.09 | 0.9218 | 4.56 | 5.21 | 2,415,173.00 | 11.05 | 9.08 | 15.57 | 11.98 | 54.88 | 59.90 | 11.99 | 11.29 | 1.05 | 15.04 | 0.5206 | 18.18 | 6.96 | 11.64 | -13.89 | 10.88 | 9.72 | 7.93 |
| Getinge AB | 2.24bn | 264.14m | 6.77bn | 10.67k | 27.46 | 3.83 | 16.71 | 3.02 | 12.09 | 12.09 | 102.44 | 86.64 | 0.609 | 2.62 | 6.07 | 2,579,128.00 | 7.26 | 2.23 | 8.75 | 2.99 | 49.45 | 47.39 | 11.93 | 4.18 | 1.37 | 23.02 | 0.1878 | 46.79 | 12.27 | -0.2767 | 165.06 | 18.43 | -12.64 | 1.68 |
| Amplifon SpA | 1.62bn | 134.40m | 7.33bn | 11.27k | 54.83 | 10.41 | 23.07 | 4.54 | 0.7062 | 0.7062 | 8.47 | 3.72 | 0.6038 | 22.50 | 12.09 | 171,505.50 | 5.02 | 4.63 | 6.45 | 6.14 | 24.09 | 54.35 | 8.32 | 6.73 | 0.9493 | 9.20 | 0.6513 | 25.59 | -10.19 | 8.51 | -7.05 | 16.63 | 4.81 | 38.61 |
| Demant A/S | 1.96bn | 244.64m | 8.00bn | 17.18k | 32.51 | 9.14 | 47.18 | 4.09 | 9.12 | 9.12 | 72.92 | 32.44 | 0.7625 | 2.29 | 5.98 | 1,077,252.00 | 9.62 | 8.54 | 16.49 | 13.79 | 73.57 | 75.25 | 12.62 | 11.17 | 0.5706 | 27.25 | 0.5794 | 0.00 | -3.19 | 6.29 | -23.32 | -4.83 | 5.23 | -- |
| Carl Zeiss Meditec AG | 1.38bn | 197.68m | 10.63bn | 3.53k | 53.56 | 7.66 | -- | 7.72 | 2.65 | 2.65 | 18.47 | 18.55 | 0.7467 | 2.37 | 9.38 | 466,376.40 | 10.77 | 8.57 | 13.09 | 10.56 | 58.74 | 56.59 | 14.42 | 11.34 | 2.94 | 11.55 | 0.1055 | 36.15 | 23.31 | 8.64 | 93.06 | 19.16 | 18.81 | 16.47 |
| Smith & Nephew plc | 3.78bn | 408.00m | 11.11bn | 18.00k | 27.23 | 2.82 | 13.23 | 2.94 | 0.4635 | 0.4635 | 4.30 | 4.47 | 0.5006 | 0.8966 | 4.04 | 211,032.50 | 5.40 | 7.91 | 6.57 | 9.57 | 69.63 | 72.89 | 10.79 | 13.70 | 1.27 | 29.84 | 0.4008 | 46.96 | -11.25 | -0.3214 | -25.33 | 1.79 | 4.35 | 4.21 |
Data as of Jan 21 2022. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX
23.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2020 | 42.67m | 4.85% |
| The Vanguard Group, Inc.as of 03 Jan 2022 | 26.36m | 3.00% |
| BlackRock Fund Advisorsas of 12 Feb 2021 | 24.77m | 2.82% |
| Walter Scott & Partners Ltd.as of 03 Jan 2022 | 22.02m | 2.50% |
| Norges Bank Investment Managementas of 03 Jan 2022 | 19.06m | 2.17% |
| Rathbone Investment Management Ltd.as of 03 Jan 2022 | 16.78m | 1.91% |
| Legal & General Investment Management Ltd.as of 03 Jan 2022 | 16.58m | 1.89% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 03 Jan 2022 | 15.92m | 1.81% |
| Aviva Investors Global Services Ltd.as of 03 Jan 2022 | 10.59m | 1.20% |
| Invesco Asset Management Ltd.as of 03 Jan 2022 | 10.37m | 1.18% |
More ▼
Data from 31 Dec 2020 - 30 Sep 2021Source: FactSet Research Systems Inc.
